Grants

awarded

The METAvivor Research Program was established in 2009 with the specific goal of funding stage IV metastatic breast cancer research to one day, end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.

IAN CORBIN, PhD

University of Texas Southwestern Medical Center

Lipoprotein Omega-3 Fatty Acid Nanoparticles: A Novel Treatment for Breast Cancer Liver Metastases

Massimo Cristofanilli, MD

Northwestern University

Presented In Memory of Karen Presswood, Co-Founder of METAvivor

Unravelling New Cytokine-Mediated Mechanisms to Enhance Response to CDK4/6 inhibition in ER+/HER2-Metastatic Breast Cancer

Brad St Croix, PhD

National Cancer Institute

Presented by Monica Hill’s Be Bold and Behold, In Loving Memory of Monica Hill and Jasmine Charles

Improving the therapeutic index of ADCs targeting metastatic breast cancer

BRAD ST CROIX, PhD

National Cancer Institute

Improving Immunotherapies for Advanced Metastatic Breast Cancer

BRAD ST. CROIX, PhD

National Cancer Institute Center for Cancer Research

Improving Therapy for Metastatic Breast Cancer through Targeting of Tumor Stroma

Wei Dai, PhD

New York University Grossman School of Medicine

Presented in Memory of Jacquie Reynolds Beck & Kerry O’Riordan McAdam

Plk1 as a Key Molecular Target for Managing Metastasis of Breast Cancer

Gokul Das, PhD

Roswell Park Comprehensive Cancer Center

Presented by METAvivor’s community of followers on social media in honor of all of those touched by metastatic breast cancer

Repurposing Tamoxifen to Treat Molecularly Stratified Metastatic Triple Negative Breast Cancer

Bisrat Debeb, DVM, PhD

The University of Texas MD Anderson Cancer Center

Targeting sEcad – PDI axis for the treatment of breast cancer brain metastasis

JOSHUA DONALDSON, MD, PhD

Johns Hopkins University

Resistance Mechanisms to Palbociclib in Hormone Positive Metastatic Breast Cancer

VERA DONNENBERG, PhD

University of Pittsburgh School of Medicine UPMC Hillman Cancer Center

Assays to determine optimal dosing and therapeutic effects of localized immunotherapy for established metastatic breast cancer t

Joshua Drago, MD

Memorial Sloan Kettering Cancer

Presented by METAvivors of New Jersey

The intestinal microbiome and response to chemoimmunotherapy in patients with metastatic triple negative breast cancer (MTNBC)

GLORIA ECHEVERRIA, PhD

MD Anderson Cancer Center

Elucidation and functionalization of transcriptomic heterogeneity of established multi-organ metastases in patient-derived xenog